Titre:
  • Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
Auteur:Zeng, Qinghe; Klein, Christophe; Caruso, Stefano; Maille, Pascale; Allende, Daniela S; Mínguez, Beatriz; Iavarone, Massimo; Ningarhari, Massih; Casadei-Gardini, Andrea; Pedica, Federica; Rimini, Margherita; Perbellini, Riccardo; Boulagnon-Rombi, Camille; Heurgué, Alexandra; Maggioni, Marco; Trepo, Eric; Vij, Mukul; Baulande, Sylvain; Legoix, Patricia; Lameiras, Sonia; HCC-AI study group, Léa; Bruges, Viviane; Gnemmi, Jean Charles; Nault, Claudia; Campani, Hyungjin; Rhee, Young Nyun; Park, Mercedes; Iñarrairaegui, Guillermo; Garcia-Porrero, Josepmaria; Argemi, Bruno; Sangro, Antonio; D'Alessio, Bernhard; Scheiner, David James; Pinato, Matthias; Pinter, Valérie; Paradis, Aurélie; Beaufrère, Simon; Peter, Lorenza; Rimassa, Luca; Di Tommaso, Arndt; Vogel, Sophie; Michalak, Jérôme; Boursier, Nicolas; Loménie, Marianne; Ziol, Julien; Calderaro,
Informations sur la publication:Lancet oncology, 24, 12, page (1411-1422)
Statut de publication:Publié, 2023-12-01
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adult
Humans
Male
Female
Adolescent
Bevacizumab
Carcinoma, Hepatocellular -- drug therapy -- genetics
Retrospective Studies
Artificial Intelligence
Liver Neoplasms -- drug therapy -- genetics
Biomarkers
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Langue:Anglais
Identificateurs:urn:issn:1470-2045
info:doi/10.1016/S1470-2045(23)00468-0
info:pii/S1470-2045(23)00468-0
info:pmid/37951222